CBE
MCID: CHR682
MIFTS: 37

Chronic Bilirubin Encephalopathy (CBE)

Categories: Metabolic diseases, Neuronal diseases, Rare diseases

Aliases & Classifications for Chronic Bilirubin Encephalopathy

MalaCards integrated aliases for Chronic Bilirubin Encephalopathy:

Name: Chronic Bilirubin Encephalopathy 58
Bilirubin-Induced Neurological Dysfunction 58
Kernicterus Spectrum Disorder 58
Bind 58
Cbe 58
Ksd 58

Classifications:

Orphanet: 58  
Rare neurological diseases
Inborn errors of metabolism


Summaries for Chronic Bilirubin Encephalopathy

MalaCards based summary : Chronic Bilirubin Encephalopathy, also known as bilirubin-induced neurological dysfunction, is related to von willebrand disease, type 2 and cold agglutinin disease. The drugs Valproic acid and Lorazepam have been mentioned in the context of this disorder. Affiliated tissues include prostate, liver and t cells, and related phenotypes are prolonged neonatal jaundice and neonatal hyperbilirubinemia

Wikipedia : 74 Kernicterus is a bilirubin-induced brain dysfunction. The term was coined in 1904 by Schmorl. Bilirubin... more...

Related Diseases for Chronic Bilirubin Encephalopathy

Diseases in the Acute Bilirubin Encephalopathy family:

Chronic Bilirubin Encephalopathy

Diseases related to Chronic Bilirubin Encephalopathy via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 656)
# Related Disease Score Top Affiliating Genes
1 von willebrand disease, type 2 11.0
2 cold agglutinin disease 11.0
3 retinoblastoma 10.9
4 alzheimer disease 10.9
5 niemann-pick disease, type c1 10.9
6 asthma 10.9
7 cervical cancer 10.9
8 sclerosteosis 10.9
9 pseudo-von willebrand disease 10.8
10 zinc finger protein 103 10.8
11 zinc finger protein 105 10.8
12 zinc finger protein 106 10.8
13 zinc finger protein 109 10.8
14 pyogenic sterile arthritis, pyoderma gangrenosum, and acne 10.8
15 hepatic lipase deficiency 10.8
16 penile cancer 10.8
17 neuromyelitis optica 10.8
18 episodic ataxia 10.8
19 factor v leiden thrombophilia 10.8
20 complement receptor deficiency 10.8
21 cytokine receptor deficiency 10.8
22 transcobalamin deficiency 10.8
23 serpinopathy 10.8
24 helix syndrome 10.5
25 rapidly involuting congenital hemangioma 10.5
26 human immunodeficiency virus type 1 10.4
27 kernicterus 10.4
28 encephalopathy 10.4
29 bilirubin metabolic disorder 10.4
30 herpes simplex 10.3
31 influenza 10.3
32 hepatitis c virus 10.2
33 severe acute respiratory syndrome 10.2
34 neuroblastoma 10.2
35 immune deficiency disease 10.2
36 alpha/beta t-cell lymphopenia with gamma/delta t-cell expansion, severe cytomegalovirus infection, and autoimmunity 10.2
37 amyotrophic lateral sclerosis 1 10.2
38 major depressive disorder 10.2
39 mental depression 10.2
40 lateral sclerosis 10.2
41 depression 10.2
42 dengue virus 10.2
43 lupus erythematosus 10.2
44 47,xyy 10.2
45 purpura 10.1
46 avian influenza 10.1
47 t-cell lymphoblastic leukemia/lymphoma 10.1
48 leukemia, t-cell, chronic 10.1
49 autoimmune disease 10.1
50 systemic lupus erythematosus 10.1

Graphical network of the top 20 diseases related to Chronic Bilirubin Encephalopathy:



Diseases related to Chronic Bilirubin Encephalopathy

Symptoms & Phenotypes for Chronic Bilirubin Encephalopathy

Human phenotypes related to Chronic Bilirubin Encephalopathy:

58 31 (show all 22)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 prolonged neonatal jaundice 58 31 hallmark (90%) Very frequent (99-80%) HP:0006579
2 neonatal hyperbilirubinemia 58 31 hallmark (90%) Very frequent (99-80%) HP:0003265
3 abnormal auditory evoked potentials 58 31 hallmark (90%) Very frequent (99-80%) HP:0006958
4 hepatic encephalopathy 58 31 hallmark (90%) Very frequent (99-80%) HP:0002480
5 intellectual disability 58 31 frequent (33%) Frequent (79-30%) HP:0001249
6 sensorineural hearing impairment 58 31 frequent (33%) Frequent (79-30%) HP:0000407
7 hypertonia 58 31 frequent (33%) Frequent (79-30%) HP:0001276
8 fever 58 31 frequent (33%) Frequent (79-30%) HP:0001945
9 hemolytic anemia 58 31 frequent (33%) Frequent (79-30%) HP:0001878
10 cerebral palsy 58 31 frequent (33%) Frequent (79-30%) HP:0100021
11 hypoalbuminemia 58 31 frequent (33%) Frequent (79-30%) HP:0003073
12 feeding difficulties 58 31 frequent (33%) Frequent (79-30%) HP:0011968
13 central apnea 58 31 frequent (33%) Frequent (79-30%) HP:0002871
14 abnormal thalamic mri signal intensity 58 31 frequent (33%) Frequent (79-30%) HP:0012696
15 kernicterus 58 31 frequent (33%) Frequent (79-30%) HP:0001343
16 conjunctival icterus 58 31 frequent (33%) Frequent (79-30%) HP:0032106
17 seizure 31 frequent (33%) HP:0001250
18 hypernatremia 58 31 occasional (7.5%) Occasional (29-5%) HP:0003228
19 neonatal sepsis 58 31 occasional (7.5%) Occasional (29-5%) HP:0040187
20 visual gaze preference 58 31 occasional (7.5%) Occasional (29-5%) HP:0025518
21 seizures 58 Frequent (79-30%)
22 abnormal conjunctiva morphology 58 Frequent (79-30%)

Drugs & Therapeutics for Chronic Bilirubin Encephalopathy

Drugs for Chronic Bilirubin Encephalopathy (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 700)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Valproic acid Approved, Investigational Phase 4 99-66-1 3121
2
Lorazepam Approved Phase 4 846-49-1 3958
3
BCG vaccine Approved, Investigational Phase 4
4
Bleomycin Approved, Investigational Phase 4 11056-06-7 5360373
5
Vancomycin Approved Phase 4 1404-90-6 441141 14969
6
Hyaluronic acid Approved, Vet_approved Phase 4 9004-61-9 53477741
7
Zinc Approved, Investigational Phase 4 7440-66-6 32051
8
Glyburide Approved Phase 4 10238-21-8 3488
9
Montelukast Approved Phase 4 158966-92-8 5281040
10
Temocillin Approved, Investigational Phase 4 66148-78-5
11
Testosterone enanthate Approved Phase 4 315-37-7 9416
12
Testosterone undecanoate Approved, Investigational Phase 4 5949-44-0
13
Testolactone Approved, Investigational Phase 4 968-93-4 13769
14
Methyltestosterone Approved Phase 4 58-18-4 6010
15 Lynestrenol Approved, Investigational Phase 4 52-76-6
16
Cyproterone Acetate Approved, Investigational Phase 4 427-51-0
17
Penicillamine Approved Phase 4 52-67-5 5852 4727
18
Dimenhydrinate Approved Phase 4 523-87-5 441281
19
Parathyroid hormone Approved, Investigational Phase 4 9002-64-6
20
Deferasirox Approved, Investigational Phase 4 201530-41-8 5493381 214348
21
Deferoxamine Approved, Investigational Phase 4 70-51-9 2973
22
Levetiracetam Approved Phase 4 102767-28-2 441341
23
Carbamazepine Approved, Investigational Phase 4 298-46-4 2554
24
Dimethyl fumarate Approved, Investigational Phase 4 624-49-7 637568 5271565
25 Brodalumab Approved, Investigational Phase 4 1174395-19-7
26
Citalopram Approved Phase 4 59729-33-8 2771
27
Aripiprazole Approved, Investigational Phase 4 129722-12-9 60795
28
Sertraline Approved Phase 4 79617-96-2 68617
29
Angiotensin II Approved, Investigational Phase 4 68521-88-0, 4474-91-3, 11128-99-7 172198
30
Losartan Approved Phase 4 114798-26-4 3961
31
Azithromycin Approved Phase 4 83905-01-5 55185 447043
32
Evolocumab Approved Phase 4 1256937-27-5
33
afatinib Approved Phase 4 850140-72-6, 439081-18-2 10184653
34
Colestipol Approved Phase 4 26658-42-4
35
Eprosartan Approved Phase 4 133040-01-4 5281037
36
Telmisartan Approved, Investigational Phase 4 144701-48-4 65999
37
Olmesartan Approved, Investigational Phase 4 144689-24-7, 144689-63-4 158781 130881
38
Irbesartan Approved, Investigational Phase 4 138402-11-6 3749
39
Candesartan cilexetil Approved Phase 4 145040-37-5 2540
40
Valsartan Approved, Investigational Phase 4 137862-53-4 60846
41
Ravulizumab Approved, Investigational Phase 4 1803171-55-2
42
Protein C Approved Phase 4
43
Apomorphine Approved, Investigational Phase 4 58-00-4, 41372-20-7 6005
44
Pimavanserin Approved, Investigational Phase 4 706779-91-1 16058810
45
Adenosine Approved, Investigational Phase 4 58-61-7 60961
46
Clopidogrel Approved Phase 4 120202-66-6, 113665-84-2 60606
47
Aspirin Approved, Vet_approved Phase 4 50-78-2 2244
48
Ticagrelor Approved Phase 4 274693-27-5 9871419
49
Glutamic acid Approved, Nutraceutical Phase 4 56-86-0 33032
50
Vitamin C Approved, Nutraceutical Phase 4 50-81-7 5785 54670067

Interventional clinical trials:

(show top 50) (show all 754)
# Name Status NCT ID Phase Drugs
1 The Efficacy of Intra-lesional Bleomycin Versus Intra-lesional Purified Protein Derivative in Treatment of Palmoplantar Warts Unknown status NCT03477448 Phase 4 Bleomycin;Purified Protein Derivative
2 Exploring Vancomycin Disposition in Neonates: Paired Analysis of Vancomycin Concentrations Using Immunoassay and Liquid-chromatography-tandem Mass Spectrometry. Determination of Vancomycin Protein Binding and Its Covariates in Neonates Unknown status NCT02096536 Phase 4 Vancomycin
3 The Impact of Omega-3 Supplementation on Acylation Stimulating Protein(ASP), Retinol-binding Protein 4 (RBP4) and Lipocalin-2 (LCN2) Gene Expression of ASP Receptor (C5L2) in WBC of Patient With Diabetes Type 2 Unknown status NCT01478776 Phase 4
4 Management of Active and Established Corneal Neovascularisation to Prevent Visual Impairment Unknown status NCT02594423 Phase 4 Bevacizumab
5 Prospective Assessment of Valproate on Ethanol Withdrawal Unknown status NCT03235531 Phase 4 Valproate;Lorazepam
6 International Multicenter Double-bind Placebo-controlled Randomized Parallel-group Clinical Trial of Anaferon for Children Efficacy in Prevention of Influenza and Other Acute Respiratory Viral Infections in Children During the Peaks of Seasonal Morbidity Completed NCT03301155 Phase 4 Anaferon for children;Placebo
7 Prospective, Pivotal Unicentre, Randomized Double-bind, Placebo-controlled Study, to Evaluate Efficacy and Safety of Bacterial Lysates (Pulmonarom) in the Prevention of Respiratory Tract Infections Completed NCT00599417 Phase 4 Bacterial Lysates;placebo
8 An Open-label, Prospective, Multicenter Study to Investigate the Specificity of in Vivo Antibody Binding to Red Blood Cells in Subjects With Chronic Immune Thrombocytopenic Purpura (ITP) Treated With IgPro10 (Privigen®) Who Have Shown Signs of Hemolysis Completed NCT01390649 Phase 4
9 The Influence of Sex Steroid Hormones on Serotonin Transporter Binding in the Human Brain Investigated by Positron Emission Tomography Completed NCT01065220 Phase 4 Testolactone undecanoate;Lynestrenol;Cyproterone Acetate;Estradiol;5-alpha reductase inhibitor
10 Effect of Increasing Doses of Cystine Binding Thiol Drugs on Cystine Capacity in Patients With Cystinuria Completed NCT02125721 Phase 4 CBTD 0-3 gm
11 Effect of the R230C Variant of the ATP-binding Cassette Transporter A1 (ABCA1) Gene on the Response to Treatment With Glibenclamide in Patients With Type 2 Diabetes Mellitus Completed NCT01456650 Phase 4 Glyburide
12 Evaluation of Sperm Selection Technique Using Hyaluronic Acid Binding in Intra-cytoplasmic Sperm Injection (ICSI) Completed NCT03999372 Phase 4
13 Effects of Electroconvulsive Therapy on Serotonin-1A Receptor Binding in Major Depression Completed NCT00922064 Phase 4
14 The Use of MI Varnish for the Prevention and Reduction of White Spot Lesions in Orthodontic Treatment Completed NCT03446690 Phase 4 MI Varnish
15 Different Conbercept Injection Methods in Treatment of Severe Proliferative Diabetic Retinopathy Completed NCT02816710 Phase 4 Conbercept
16 Pilot Pharmacokinetic Study In Patients With Inadequate Response To Deferasirox (Exjade) Completed NCT00749515 Phase 4 Deferoxamine;Deferasirox
17 Assessment of the Effect of Vitamin C on Anemia in Patients With Continuous Ambulatory Peritoneal Dialysi Completed NCT02780505 Phase 4 vitamin c;placebo
18 Diagnostic Accuracy Study of Indocyanine Green for Parathyroid Perfusion Assessment Completed NCT03969108 Phase 4 Indocyanine Green
19 A Clinical Pharmacokinetic Study: Is Three Times Weekly Temocillin Appropriate for the Treatment of Severe Gram-negative Infections in Patients With ESRD Treated With Intermittent Hemodialysis? Completed NCT02285075 Phase 4 temocillin PK/PD in haemodialysis
20 Role of Montelukast in Asthma and Allergic Rhinitis Patients Completed NCT03380975 Phase 4 Montelukast 10mg
21 The Effects on Cognitive Function of Levetiracetam (Keppra®) Compared to Carbamazepine (Tegretol®, Carmazepine®) as Monotherapy for Children With Partial Seizure; A Multicentric Randomized Controlled Study Completed NCT02208492 Phase 4 Levetiracetam;Carabamazepine
22 A Phase 4 Trial Comparing the Efficacy of Subcutaneous Injections of Brodalumab to Oral Administrations of Fumaric Acid Esters in Adults With Moderate to Severe Plaque Psoriasis Completed NCT03331835 Phase 4 Fumaric acid esters
23 Personalized Indications for Cognitive Behavioural Therapy and Antidepressants in the Treatment of Major Depressive Disorder and Persistent Depressive Disorder Recruiting NCT02752542 Phase 4 Pharmacotherapy
24 A Pilot Study to Evaluate 18F Florbetapir Binding to Cardiac Amyloid in Patients Undergoing Chemotherapy Recruiting NCT03333551 Phase 4 F18 Florbetapir (amyvid) cardiac PET/CT imaging
25 Prospective, Single-arm, Open-label Use of Hemlibra (Emicizumab) to Treat Hemophilic Pseudotumor Recruiting NCT03921294 Phase 4 Emicizumab
26 An Open Label Randomised Controlled Trial of Azithromycin Versus Ciprofloxacin for the Treatment of Children Hospitalised With Dysentery in Ho Chi Minh City, Vietnam Recruiting NCT03854929 Phase 4 Ciprofloxacin;Azithromycin
27 An Open-label, Single-arm Clinical Study to Evaluate the Efficacy of Afatinib in Advanced Lung Squamous Cell Carcinoma With EGFR Sensitive Mutation Recruiting NCT04132102 Phase 4 Afatinib
28 A Randomized Trial of Evolocumab on Saphenous Vein Graft Patency Following Coronary Artery Bypass Surgery (NEWTON-CABG) Recruiting NCT03900026 Phase 4 Evolocumab
29 Treatment Effect of Colesevelam for Bile Acid Diarrhoea - a Randomised Placebo-controlled Trial Recruiting NCT03876717 Phase 4 Colesevelam Hydrochloride;Placebo oral capsule
30 Controlled evaLuation of Angiotensin Receptor Blockers for COVID-19 respIraTorY Disease Recruiting NCT04394117 Phase 4 Angiotensin Receptor Blockers
31 mulTi-Arm Therapeutic Study in Pre-ICu Patients Admitted With Covid-19 - Repurposed Drugs (TACTIC-R) Recruiting NCT04390464 Phase 4 Ravulizumab;Baricitinib
32 Double Bind Randomized Placebo-controlled Cross-over Study to Evaluate Effect of Continuous Apomorphine During the Night on Sleep Disorders in Insomniac Patients With Parkinson's Disease Active, not recruiting NCT02940912 Phase 4 Apomorphine;Placebo
33 An Open Label Trial to Assess the Safety and Efficacy of KRN23, an Investigational Antibody to FGF23, in a Single Pediatric Patient With Epidermal Nevus Syndrome (ENS) and Associated Hypophosphatemic Rickets Active, not recruiting NCT04320316 Phase 4 Crysvita (burosumab-twza) Treatment
34 A Phase IV Randomised Clinical Trial of Laser Therapy for Peripheral Retinal Ischaemia Combined With Intravitreal Aflibercept (Eylea®) Versus Intravitreal Aflibercept Monotherapy for Diabetic Macular Oedema Active, not recruiting NCT02432547 Phase 4 Aflibercept
35 CSP #2015 - Multicenter, Randomized, Double-blind Comparator Study of Antipsychotics Pimavanserin and Quetiapine for Parkinson''s Disease Psychosis (C-SAPP) Not yet recruiting NCT04373317 Phase 4 Pimavanserin;Quetiapine
36 Prospective, Single-Arm, Open-Label Use of Hemlibra (Emicizumab) in the Treatment of Mild Hemophilia A Not yet recruiting NCT04567511 Phase 4 Emicizumab
37 Serum Calprotectin Level in Patients With Rheumatoid Arthritis and Osteoarthritis Not yet recruiting NCT04201886 Phase 4
38 Multicenter, Double-bind, Randomised, Placebo Controlled Study of Ulinastatin in Severe Acute Pancreatitis Suspended NCT01132521 Phase 4 ulinastatin;placebo
39 Impact of Ticagrelor and Aspirin Versus Clopidogrel and Aspirin in Patients With Claudication and Peripheral Arterial Disease (PAD): Thrombus Burden Assessed by Optical Coherence Tomography Terminated NCT02407314 Phase 4 Aspirin;Aspirin + Ticagrelor
40 Association of Serum Levels of Lipopolysaccharide Binding Protein (LBP) With the Evolution of Pro- and Anti-inflammatory Cytokines, and the Development of Severe Infectious Events in Cirrhotic Patients Withdrawn NCT00760032 Phase 4 Ciprofloxacin;Placebo
41 Effect of CPP-ACP Pastes With/Without Fluoride on White Spot Lesion Progression, Salivary pH and Fluoride Release in High Caries Risk Patients A Randomized Clinical Trial Unknown status NCT03656432 Phase 3 CPP-ACP paste
42 Multicenter Double-bind Randomized Trial of Ferric Carboxymaltose With or Without Erythropoietin for the Prevention of Red-cell Transfusion in Hip Fracture Perioperative Period. Completed NCT01154491 Phase 3 Ferric carboxymaltose;Erythropoietin;Placebo
43 A Multinational, Multi-Center, Randomised, Double-Bind, Placebo-Controlled, Parallel Group Study to Assess the Safety and Efficacy of a Subject Optimised Dose of Sildenafil Citrate (20, 40, or 80 mg. Sildenafil Citrate TID) Based on the Toleration, When Used in Combination With Intravenous Prostacyclin( Epoprostenol) in the Treatment of Pulmonary Arterial Hypertension. Completed NCT00159861 Phase 3 Sildenafil citrate
44 Rituximab in Adult's Warm Auto-Immune Hemolytic Anemia : a Phase III, Double-bind, Randomised Placebo-controlled Trial Completed NCT01181154 Phase 3 rituximab (Mabthera®);Placebo
45 A Randomized, Double-Bind, Placebo-Controlled, Parallel-Group, Fixed-Dose, Multicenter Study to Assess Efficacy and Safety of Rimonabant 20 mg Versus Placebo on Weight Loss and Frequency of Binge Episodes in Obese Patients With Food Craving Completed NCT00481975 Phase 3 rimonabant (SR141716)
46 A Randomized, Double-Bind, Placebo-Controlled, Parallel-Group, Fixed-Dose (20 mg/Day), 3-Month, Multicenter Study of the Energy Intake Effects and Safety of SR141716 With or Without Hypocaloric Diet in Obese Patients Completed NCT00481923 Phase 3 rimonabant (SR141716)
47 Brain Imaging and Treatment Studies of the Night Eating Syndrome Completed NCT01401595 Phase 3 escitalopram oxalate
48 A Multicenter, Double-blind, Randomized Withdrawal Extension Study of Subcutaneous Secukinumab in Prefilled Syringes to Demonstrate Long-term Efficacy, Safety, and Tolerability up to 4 Years in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis Completing Preceding Psoriasis Phase III Studies With Secukinumab Completed NCT01544595 Phase 3 Secukinumab (AIN457);Placebo
49 A Three-year Extension Study to Evaluate the Long Term Efficacy, Safety and Tolerability of Secukinumab in Patients With Active Psoriatic Arthritis Completed NCT01892436 Phase 3 Secukinumab;Placebo
50 A Laser Detection for Bladder Cancer by (Photodynamic) Spectra of Urine Completed NCT02101931 Phase 3 Amino levulinic Acid

Search NIH Clinical Center for Chronic Bilirubin Encephalopathy

Genetic Tests for Chronic Bilirubin Encephalopathy

Anatomical Context for Chronic Bilirubin Encephalopathy

MalaCards organs/tissues related to Chronic Bilirubin Encephalopathy:

40
Prostate, Liver, T Cells, Brain, Bone, Lung, Thyroid

Publications for Chronic Bilirubin Encephalopathy

Articles related to Chronic Bilirubin Encephalopathy:

(show all 40)
# Title Authors PMID Year
1
A greater awareness of children with glucose-6-phosphate dehydrogenase deficiency is imperative in western countries. 61
33560519 2021
2
Neonatal Indirect Hyperbilirubinemia. 61
33139512 2020
3
Traditional African remedies induce hemolysis in a glucose-6-phopshate dehydrogenase deficient zebrafish model. 61
33154437 2020
4
[An update on unconjugated neonatal hyperbilirubinaemia in Denmark]. 61
32285792 2020
5
Management of neonatal jaundice in low- and middle-income countries. 61
31875773 2020
6
Extreme neonatal hyperbilirubinemia and kernicterus spectrum disorder in Denmark during the years 2000-2015. 61
31907395 2020
7
TcB, FFR, phototherapy and the persistent occurrence of kernicterus spectrum disorder. 61
31911651 2020
8
Case study on the use of intensive pediatric neurorehabilitation in the treatment of kernicterus. 61
32042435 2020
9
Bilirubin Induced Encephalopathy. 61
32021624 2020
10
Review of bilirubin neurotoxicity I: molecular biology and neuropathology of disease. 61
31600770 2020
11
The Choice of Population and Outcomes in Neonatal Trials on Hyperbilirubinemia: Are They Relevant? An Analysis of Cochrane Neonatal Reviews. 61
33264799 2020
12
[Clinical characteristics and treatment options of hearing impairment caused by hyperbilirubinemia]. 61
31446717 2019
13
Prebiotics for the prevention of hyperbilirubinaemia in neonates. 61
31425619 2019
14
Hyperbilirubinemia in preterm infants in Japan: New treatment criteria. 61
29906300 2018
15
Extreme neonatal hyperbilirubinemia, acute bilirubin encephalopathy, and kernicterus spectrum disorder in children with galactosemia. 61
29892033 2018
16
Variation in the Phototherapy Practices and Irradiance of Devices in a Major Metropolitan Area. 61
29393277 2018
17
Newborn Bilirubin Screening for Preventing Severe Hyperbilirubinemia and Bilirubin Encephalopathy: A Rapid Review. 61
28071585 2017
18
Facility-based constraints to exchange transfusions for neonatal hyperbilirubinemia in resource-limited settings. 61
27170928 2016
19
A Hypothesis for Using Pathway Genetic Load Analysis for Understanding Complex Outcomes in Bilirubin Encephalopathy. 61
27587993 2016
20
Risk factors for acute bilirubin encephalopathy on admission to two Myanmar national paediatric hospitals. 61
27057339 2015
21
Galactosaemia: an unusual cause of chronic bilirubin encephalopathy. 61
25618877 2015
22
Magnetic resonance imaging of bilirubin encephalopathy: current limitations and future promise. 61
25267277 2014
23
Evaluation and treatment of neonatal hyperbilirubinemia. 61
25077393 2014
24
Outcome analysis of jaundice fast-track system implementation in Thammasat University Hospital. 61
25065088 2014
25
[Crigler-Najjar's syndrome is a rare cause of perinatal hyperbilirubinaemia]. 61
24629117 2013
26
[Crigler-Najjar type 1 in children]. 61
24629116 2013
27
Incidence of chronic bilirubin encephalopathy in Canada, 2007-2008. 61
22966025 2012
28
Relation between serum bilirubin levels ≥450 μmol/L and bilirubin encephalopathy; a Danish population-based study. 61
22176133 2012
29
Birth-related syndromes of athetosis and kernicterus. 61
21496597 2011
30
Putting prevention into practice. Screening of infants for hyperbilirubinemia to prevent chronic bilirubin encephalopathy. 61
20704173 2010
31
Screening of infants for hyperbilirubinemia to prevent chronic bilirubin encephalopathy: recommendation statement. 61
20704172 2010
32
Assessing jaundice in infants of 35-week gestation and greater. 61
20463489 2010
33
Chronic bilirubin encephalopathy: diagnosis and outcome. 61
20116355 2010
34
Systematic review of screening for bilirubin encephalopathy in neonates. 61
19786450 2009
35
Screening of infants for hyperbilirubinemia to prevent chronic bilirubin encephalopathy: US Preventive Services Task Force recommendation statement. 61
19786451 2009
36
An emergency medicine approach to neonatal hyperbilirubinemia. 61
17950138 2007
37
[Incidence of kernicterus in newborn infants in Denmark]. 61
16494808 2006
38
Clinical (video) findings and cerebrospinal fluid neurotransmitters in 2 children with severe chronic bilirubin encephalopathy, including a former preterm infant without marked hyperbilirubinemia VIDEO. 61
16264013 2005
39
Neurological complications of kernicterus. 61
16225171 2005
40
Follow-up study of auditory brainstem responses in hyperbilirubinemic newborns treated with exchange transfusion. 61
8992853 1996

Variations for Chronic Bilirubin Encephalopathy

Expression for Chronic Bilirubin Encephalopathy

Search GEO for disease gene expression data for Chronic Bilirubin Encephalopathy.

Pathways for Chronic Bilirubin Encephalopathy

GO Terms for Chronic Bilirubin Encephalopathy

Sources for Chronic Bilirubin Encephalopathy

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Mar-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....